QUIBRON-T Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Quibron-t, and when can generic versions of Quibron-t launch?
Quibron-t is a drug marketed by Monarch Pharms and is included in two NDAs.
The generic ingredient in QUIBRON-T is theophylline. There are thirty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the theophylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Quibron-t
A generic version of QUIBRON-T was approved as theophylline by RHODES PHARMS on September 1st, 1982.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for QUIBRON-T?
- What are the global sales for QUIBRON-T?
- What is Average Wholesale Price for QUIBRON-T?
Summary for QUIBRON-T
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 171 |
| Patent Applications: | 3,990 |
| DailyMed Link: | QUIBRON-T at DailyMed |
US Patents and Regulatory Information for QUIBRON-T
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Monarch Pharms | QUIBRON-T | theophylline | TABLET;ORAL | 088656-001 | Aug 22, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Monarch Pharms | QUIBRON-T/SR | theophylline | TABLET, EXTENDED RELEASE;ORAL | 087563-001 | Jun 21, 1983 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
